What are the risks of radioactive iodine (RAI) therapy in a patient with papillary thyroid carcinoma (PTC) and scalp metastases?

Danger of RAI for PTC with Scalp Metastases

RAI therapy can be safely administered to patients with papillary thyroid carcinoma and scalp metastases, as these cutaneous metastases often retain radioiodine avidity and represent treatable disease, though specific risks include potential radiation injury to superficial tissues and the general complications associated with RAI therapy.

Understanding the Clinical Context

Scalp metastases from PTC are exceptionally uncommon but can retain radioiodine uptake capability. A recent case report 1 documented multiple radioiodine-avid cutaneous metastases including scalp involvement detected on post-therapy 131I SPECT/CT, demonstrating that these lesions can concentrate radioiodine and potentially respond to treatment. This represents distant metastatic disease (M1), placing the patient in a high-risk category.

Specific Risks with Scalp Metastases

Localized Radiation Effects

• Superficial tissue damage: Scalp metastases are particularly vulnerable because they lie close to the skin surface with minimal tissue depth for radiation dispersion
• Potential for radiation dermatitis: The concentrated radioiodine in superficial lesions can cause localized skin reactions, hair loss in the affected area, and tissue necrosis
• Risk of wound complications: If lesions are near surgical sites or areas of prior trauma

General RAI Complications

The standard complications of RAI therapy apply 2:

Acute risks (occurring within days to weeks):

• Nausea and vomiting
• Ageusia (loss of taste)
• Salivary gland swelling and pain
• Sialadenitis

Long-term complications:

• Recurrent sialoadenitis with xerostomia (dry mouth)
• Dental caries from reduced salivary function
• Nasolacrimal duct obstruction
• Pulmonary fibrosis (particularly relevant if lung metastases coexist)
• Second primary malignancies (dose-dependent risk)

Treatment Decision Algorithm

For PTC with scalp metastases, follow this approach:

1. Confirm radioiodine avidity: Perform diagnostic whole-body scan or use post-therapy imaging to verify iodine uptake in metastatic lesions

2. Assess disease burden and progression:

   • If lesions are RAI-avid and surgically unresectable → Proceed with RAI therapy 3
   • If disease is clinically progressive despite RAI → Consider systemic kinase inhibitors (lenvatinib preferred) 3

3. Consider surgical debulking first if:

   • Scalp lesions are large, symptomatic, or causing local complications
   • Surgical resection can reduce tumor burden before RAI

4. RAI dosing considerations:

   • Higher activities (150-200 mCi) typically used for distant metastases
   • Monitor for enhanced local radiation effects to scalp lesions

Critical Caveats

• RAI-refractory disease: If scalp metastases do not concentrate radioiodine or progress despite RAI, systemic therapy with kinase inhibitors becomes the primary treatment modality 3

• Contraindications to RAI 4:

  • Pregnancy or breastfeeding (absolute contraindication)
  • Iodine allergy
  • Nodular thyroid disease with heart disease

• Monitoring requirements: Close follow-up for both local skin reactions at metastatic sites and systemic RAI complications

Prognosis Context

The presence of distant metastases (including scalp involvement) places this patient in the high-risk category with estimated recurrence rates >20% 5. However, RAI therapy remains a cornerstone treatment for radioiodine-avid metastatic disease. The benefits of treating iodine-avid metastatic disease generally outweigh the risks of localized radiation effects, though patients should be counseled about potential scalp-specific complications including localized alopecia and skin changes.